BioCentury | Oct 22, 2007
Analyst Picks & Changes

Analyst picks & changes

...Other Market outperform Cowen Eric Schmidt Other Neutral Credit Suisse Michael Aberman Price target Neutral Ferris, Baker Watts...
BioCentury | Jan 1, 2007
Finance

Ebb & Flow

...shares at $2.05. The deal completed on Dec. 22. Rodman was the placement agent and Ferris, Baker Watts...
BioCentury | Dec 27, 2006
Financial News

GenVec raises $19.7 million

...close of $2.56 last Tuesday, before the offering was announced. Rodman was placement agent and Ferris, Baker Watts...
BioCentury | Dec 21, 2006
Financial News

GenVec planning offering

...a 20% discount to GNVC's close of $2.56 on Tuesday. Rodman is placement agent and Ferris, Baker Watts...
BioCentury | Feb 9, 2006
Financial News

Immtech raises $16 million

...million through the sale of 2 million shares at $8 in a follow-on underwritten by Ferris, Baker Watts...
BioCentury | Oct 29, 2005
Financial News

Accentia prices IPO

Specialty pharma company Accentia (ABPI) raised $19.2 million in an IPO through the sale of 2.4 million shares at $8, giving it a post-money valuation of $231 million. The underwriters were Jefferies; Ferris Baker Watts;...
BioCentury | Sep 12, 2005
Finance

Ebb & Flow

In 2005, the size of a typical series A round has been $15.1 million - roughly 50% higher than previous years. August saw a flurry of even larger A rounds for preclinical companies, which is surprising...
BioCentury | Sep 7, 2005
Financial News

Accentia trims IPO

Specialty pharma company Accentia (Tampa, Fla.) trimmed the shares and the price range of its IPO and now hopes to sell 2.5 million shares at $8-$10. A $9 deal price would raise $22.5 million and...
BioCentury | May 19, 2005
Financial News

Accentia amends IPO

Specialty pharma company Accentia (Tampa, Fla.) amended its IPO and now hopes to sell 5.3 million shares at $11-$13. A $12 deal price would raise $63 million and value the company at $375 million. Underwriters...
BioCentury | Feb 14, 2005
Finance

Ebb & Flow

...is in Phase III testing to treat non-Hodgkin's lymphoma. Underwriters are Jefferies; Robert W. Baird; Ferris, Baker Watts...
Items per page:
1 - 10 of 11
BioCentury | Oct 22, 2007
Analyst Picks & Changes

Analyst picks & changes

...Other Market outperform Cowen Eric Schmidt Other Neutral Credit Suisse Michael Aberman Price target Neutral Ferris, Baker Watts...
BioCentury | Jan 1, 2007
Finance

Ebb & Flow

...shares at $2.05. The deal completed on Dec. 22. Rodman was the placement agent and Ferris, Baker Watts...
BioCentury | Dec 27, 2006
Financial News

GenVec raises $19.7 million

...close of $2.56 last Tuesday, before the offering was announced. Rodman was placement agent and Ferris, Baker Watts...
BioCentury | Dec 21, 2006
Financial News

GenVec planning offering

...a 20% discount to GNVC's close of $2.56 on Tuesday. Rodman is placement agent and Ferris, Baker Watts...
BioCentury | Feb 9, 2006
Financial News

Immtech raises $16 million

...million through the sale of 2 million shares at $8 in a follow-on underwritten by Ferris, Baker Watts...
BioCentury | Oct 29, 2005
Financial News

Accentia prices IPO

Specialty pharma company Accentia (ABPI) raised $19.2 million in an IPO through the sale of 2.4 million shares at $8, giving it a post-money valuation of $231 million. The underwriters were Jefferies; Ferris Baker Watts;...
BioCentury | Sep 12, 2005
Finance

Ebb & Flow

In 2005, the size of a typical series A round has been $15.1 million - roughly 50% higher than previous years. August saw a flurry of even larger A rounds for preclinical companies, which is surprising...
BioCentury | Sep 7, 2005
Financial News

Accentia trims IPO

Specialty pharma company Accentia (Tampa, Fla.) trimmed the shares and the price range of its IPO and now hopes to sell 2.5 million shares at $8-$10. A $9 deal price would raise $22.5 million and...
BioCentury | May 19, 2005
Financial News

Accentia amends IPO

Specialty pharma company Accentia (Tampa, Fla.) amended its IPO and now hopes to sell 5.3 million shares at $11-$13. A $12 deal price would raise $63 million and value the company at $375 million. Underwriters...
BioCentury | Feb 14, 2005
Finance

Ebb & Flow

...is in Phase III testing to treat non-Hodgkin's lymphoma. Underwriters are Jefferies; Robert W. Baird; Ferris, Baker Watts...
Items per page:
1 - 10 of 11